284 related articles for article (PubMed ID: 16685318)
1. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
Buller CE; Pate GE; Armstrong PW; O'Neill BJ; Webb JG; Gallo R; Welsh RC
Can J Cardiol; 2006 May; 22(6):511-5. PubMed ID: 16685318
[TBL] [Abstract][Full Text] [Related]
2. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
Welsh RC; Gordon P; Westerhout CM; Buller CE; O'Neill B; Armstrong PW
Catheter Cardiovasc Interv; 2007 Sep; 70(3):341-8. PubMed ID: 17295333
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
4. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
Armstrong PW;
Eur Heart J; 2006 Jul; 27(13):1530-8. PubMed ID: 16757491
[TBL] [Abstract][Full Text] [Related]
5. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
[TBL] [Abstract][Full Text] [Related]
6. [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
Silber S
Herz; 2010 Dec; 35(8):558-64. PubMed ID: 21107514
[TBL] [Abstract][Full Text] [Related]
7. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topol EJ
Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
[TBL] [Abstract][Full Text] [Related]
8. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial.
Svensson L; Aasa M; Dellborg M; Gibson CM; Kirtane A; Herlitz J; Ohlsson A; Karlsson T; Grip L
Am Heart J; 2006 Apr; 151(4):798.e1-7. PubMed ID: 16569536
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Braunwald E; Angiolillo D; Bates E; Berger PB; Bhatt D; Cannon CP; Furman MI; Gurbel P; Michelson AD; Peterson E; Wiviott S
Clin Cardiol; 2008 Mar; 31(3 Suppl 1):I2-9. PubMed ID: 18481818
[TBL] [Abstract][Full Text] [Related]
10. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
[TBL] [Abstract][Full Text] [Related]
12. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
[TBL] [Abstract][Full Text] [Related]
13. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
14. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
15. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
Wang TY; Magid DJ; Ting HH; Li S; Alexander KP; Roe MT; Peterson ED
Am Heart J; 2014 Jun; 167(6):833-9. PubMed ID: 24890532
[TBL] [Abstract][Full Text] [Related]
16. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
[TBL] [Abstract][Full Text] [Related]
17. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
19. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Brodie BR
Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
Dörler J; Edlinger M; Alber HF; Altenberger J; Benzer W; Grimm G; Huber K; Pachinger O; Schuchlenz H; Siostrzonek P; Zenker G; Weidinger F;
Eur Heart J; 2011 Dec; 32(23):2954-61. PubMed ID: 21920970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
